Analysts at Lifesci Capital issued their Q1 2025 EPS estimates for Zymeworks in a research note issued to investors on ...

根据最新的SEC文件显示，知名投资公司EcoR1 Capital, LLC在三天内大幅增持了Zymeworks Inc. (NASDAQ: ZYME )的股份，收购金额约为1310万美元。根据 InvestingPro 数据，这家制药公司目前市值为8.72亿美元，其现金储备超过债务。

Despite posting disappointing top revenue and earnings misses for Q4 last week, Zymeworks (ZYME) has seen its shares rally over 5%, thanks in ...

In a report released today, Derek Archila from Wells Fargo maintained a Hold rating on Zymeworks (ZYME – Research Report), with a price target ...

Zymeworks Inc. (ZYME) shares soared 5.4% in the last trading session to close at $11.70. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares ...

Fintel reports that on March 11, 2025, LifeSci Capital initiated coverage of Zymeworks (NasdaqGS:ZYME) with a Outperform ...

Zymeworks (NYSE:ZYME – Free Report) had its target price raised by Citigroup from $18.00 to $19.00 in a report released on ...

04. Zymeworks Inc. (ZYME) 2024年第四季度财报电话会议：Zymeworks是一家专注于开发多功能生物治疗药物的临床阶段生物技术公司，其2024年净亏损1.227亿美元，收入从2023年的7600万美元略增至7630万美元。公司拥有多个临床前和临床阶段的项目，包括ZW191（FRα靶向ADC）和ZW251（GPC3靶向ADC），后者在肝细胞癌模型中表现出色，预计2025年 ...

Zymeworks shifts focus to ZW251 for liver cancer, delaying ZW220. Q4 revenue and earnings missed estimates. GSK milestone ...

Welcome to Zymeworks fourth quarter and year-end 2024 results conference call and webcast. As a reminder, all participants are in listen-only mode and the conference is being recorded. (Operator ...

周四，花旗分析师将纳斯达克上市公司Zymeworks（NASDAQ:ZYME）的目标股价从此前的18美元上调至19美元，同时重申对该公司股票的买入评级。目前该股交易价格为13.18美元，低于分析师12美元至30美元的目标区间。根据 InvestingPro 数据显示，尽管该公司仍处于开发阶段，但其整体财务健康状况评分为"良好"，表明基本面稳健。

Zymeworks Inc (ZYME) navigates a challenging year with strategic pivots and robust partnership earnings, despite increased ...